- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY 3.70 Å
- Oligo State
- hetero-3-1-1-3-mer
- Ligands
- 15 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 2 x NAG- NAG- BMA: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 2 x NAG- NAG- BMA- MAN- MAN: alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA-MAN-MAN.7: 7 residues within 4Å:- Chain A: V.33, P.176, L.225, N.226, N.338, K.404, S.405
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA-MAN-MAN.15: 6 residues within 4Å:- Chain C: K.103, N.117, Y.134, L.136
- Chain D: E.104
- Chain E: K.54
2 PLIP interactions:1 interactions with chain D, 1 interactions with chain E- Hydrogen bonds: D:E.104, E:K.54
- 1 x NAG- NAG- BMA- MAN: alpha-D-mannopyranose-(1-3)-beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 1 x NAG- NAG- BMA- MAN- MAN- MAN: alpha-D-mannopyranose-(1-3)-alpha-D-mannopyranose-(1-6)-[alpha-D-mannopyranose-(1-3)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 1 x NAG- NAG- BMA- MAN- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 41 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG.23: 2 residues within 4Å:- Chain A: E.55, N.56
Ligand excluded by PLIPNAG.24: 2 residues within 4Å:- Chain A: N.198, T.200
Ligand excluded by PLIPNAG.25: 2 residues within 4Å:- Chain A: E.233, N.253
Ligand excluded by PLIPNAG.26: 4 residues within 4Å:- Chain A: N.265, I.286, G.399
- Ligands: NAG.30
Ligand excluded by PLIPNAG.27: 1 residues within 4Å:- Chain A: N.317
Ligand excluded by PLIPNAG.28: 6 residues within 4Å:- Chain A: I.321, N.323, Q.324, N.354, K.355, R.427
Ligand excluded by PLIPNAG.29: 3 residues within 4Å:- Chain A: N.347, D.350, R.377
Ligand excluded by PLIPNAG.30: 2 residues within 4Å:- Chain A: N.400
- Ligands: NAG.26
Ligand excluded by PLIPNAG.31: 3 residues within 4Å:- Chain A: N.226, E.257, N.406
Ligand excluded by PLIPNAG.32: 2 residues within 4Å:- Chain A: W.3, N.460
Ligand excluded by PLIPNAG.33: 3 residues within 4Å:- Chain B: E.55, N.56
- Chain H: S.18
Ligand excluded by PLIPNAG.34: 2 residues within 4Å:- Chain B: N.98, E.154
Ligand excluded by PLIPNAG.35: 3 residues within 4Å:- Chain B: K.103, N.117, Y.134
Ligand excluded by PLIPNAG.36: 3 residues within 4Å:- Chain B: N.121, K.130, R.132
Ligand excluded by PLIPNAG.37: 4 residues within 4Å:- Chain B: N.194, N.204
- Ligands: NAG-NAG.11, NAG.38
Ligand excluded by PLIPNAG.38: 4 residues within 4Å:- Chain B: N.193, K.195, N.205
- Ligands: NAG.37
Ligand excluded by PLIPNAG.39: 3 residues within 4Å:- Chain B: E.239, N.240, T.242
Ligand excluded by PLIPNAG.40: 2 residues within 4Å:- Chain B: E.233, N.253
Ligand excluded by PLIPNAG.41: 3 residues within 4Å:- Chain B: N.265, I.286, G.399
Ligand excluded by PLIPNAG.42: 5 residues within 4Å:- Chain B: T.259, T.261, H.293, N.295, T.373
Ligand excluded by PLIPNAG.43: 1 residues within 4Å:- Chain B: N.317
Ligand excluded by PLIPNAG.44: 3 residues within 4Å:- Chain B: N.323, Q.324, R.427
Ligand excluded by PLIPNAG.45: 2 residues within 4Å:- Chain B: N.400, T.402
Ligand excluded by PLIPNAG.46: 4 residues within 4Å:- Chain B: N.226, E.257, N.406
- Ligands: NAG-NAG-BMA-MAN.12
Ligand excluded by PLIPNAG.47: 3 residues within 4Å:- Chain B: W.3, N.460
- Chain H: N.97
Ligand excluded by PLIPNAG.48: 3 residues within 4Å:- Chain C: E.55, N.56
- Chain G: S.18
Ligand excluded by PLIPNAG.49: 4 residues within 4Å:- Chain C: N.198, T.200, S.238
- Ligands: NAG-NAG.18
Ligand excluded by PLIPNAG.50: 3 residues within 4Å:- Chain C: N.240, T.242, D.243
Ligand excluded by PLIPNAG.51: 3 residues within 4Å:- Chain C: N.265, I.286
- Ligands: NAG.55
Ligand excluded by PLIPNAG.52: 1 residues within 4Å:- Chain C: N.317
Ligand excluded by PLIPNAG.53: 2 residues within 4Å:- Chain C: N.323, R.427
Ligand excluded by PLIPNAG.54: 3 residues within 4Å:- Chain C: N.347, D.350, L.351
Ligand excluded by PLIPNAG.55: 4 residues within 4Å:- Chain C: P.263, R.290, N.400
- Ligands: NAG.51
Ligand excluded by PLIPNAG.56: 5 residues within 4Å:- Chain C: L.229, S.255, K.404, N.406
- Ligands: NAG-NAG-BMA-MAN-MAN-MAN.20
Ligand excluded by PLIPNAG.57: 2 residues within 4Å:- Chain C: W.3, N.460
Ligand excluded by PLIPNAG.58: 2 residues within 4Å:- Chain F: N.101, S.103
Ligand excluded by PLIPNAG.59: 2 residues within 4Å:- Chain F: R.123, N.127
Ligand excluded by PLIPNAG.60: 2 residues within 4Å:- Chain G: N.101, S.103
Ligand excluded by PLIPNAG.61: 1 residues within 4Å:- Chain G: N.127
Ligand excluded by PLIPNAG.62: 2 residues within 4Å:- Chain H: N.101, S.103
Ligand excluded by PLIPNAG.63: 3 residues within 4Å:- Chain H: R.123, E.124, N.127
Ligand excluded by PLIP- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Gorman, J. et al., Structure of Super-Potent Antibody CAP256-VRC26.25 in Complex with HIV-1 Envelope Reveals a Combined Mode of Trimer-Apex Recognition. Cell Rep (2020)
- Release Date
- 2020-04-08
- Peptides
- Envelope glycoprotein gp120: ABC
VRC26.25 Heavy Chain: D
VRC26.25 Light Chain: E
Envelope glycoprotein gp41: FGH - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
FB
EC
GD
HE
LF
AG
BH
C
- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY 3.70 Å
- Oligo State
- hetero-3-1-1-3-mer
- Ligands
- 15 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 2 x NAG- NAG- BMA: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 2 x NAG- NAG- BMA- MAN- MAN: alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 1 x NAG- NAG- BMA- MAN: alpha-D-mannopyranose-(1-3)-beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 1 x NAG- NAG- BMA- MAN- MAN- MAN: alpha-D-mannopyranose-(1-3)-alpha-D-mannopyranose-(1-6)-[alpha-D-mannopyranose-(1-3)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 1 x NAG- NAG- BMA- MAN- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 41 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Gorman, J. et al., Structure of Super-Potent Antibody CAP256-VRC26.25 in Complex with HIV-1 Envelope Reveals a Combined Mode of Trimer-Apex Recognition. Cell Rep (2020)
- Release Date
- 2020-04-08
- Peptides
- Envelope glycoprotein gp120: ABC
VRC26.25 Heavy Chain: D
VRC26.25 Light Chain: E
Envelope glycoprotein gp41: FGH - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
FB
EC
GD
HE
LF
AG
BH
C